PLX.TA - Protalix BioTherapeutics, Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILA
Currency in ILA

Valuation Measures

Market Cap (intraday) 5
191.61M
Enterprise Value 3
222.21M
Trailing P/E
N/A
Forward P/E 1
N/A
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
4.05
Price/Book (mrq)
N/A
Enterprise Value/Revenue 3
4.70
Enterprise Value/EBITDA 6
-14.84

Trading Information

Stock Price History

Beta (5Y Monthly) 2.88
52-Week Change 3-21.32%
S&P500 52-Week Change 322.86%
52 Week High 31,980.00
52 Week Low 3630.00
50-Day Moving Average 31,156.05
200-Day Moving Average 3963.64

Share Statistics

Avg Vol (3 month) 358.09k
Avg Vol (10 day) 337.47k
Shares Outstanding 51.48M
Float 14.5M
% Held by Insiders 1N/A
% Held by Institutions 1N/A
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:10
Last Split Date 3Dec 22, 2019

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin -50.76%
Operating Margin (ttm)-35.08%

Management Effectiveness

Return on Assets (ttm)-17.36%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)47.29M
Revenue Per Share (ttm)3.19
Quarterly Revenue Growth (yoy)15.50%
Gross Profit (ttm)24.94M
EBITDA -14.97M
Net Income Avi to Common (ttm)-24M
Diluted EPS (ttm)-1.62
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)21.44M
Total Cash Per Share (mrq)1.45
Total Debt (mrq)61.29M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)1.21
Book Value Per Share (mrq)-4.78

Cash Flow Statement

Operating Cash Flow (ttm)-19.68M
Levered Free Cash Flow (ttm)-1.5M